Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))

Opis bibliograficzny
Główni autorzy:	Lilja, H, Ulmert, D, Vickers, A
Format:	Journal article
Język:	English
Wydane:	2008

Podobne zapisy

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
od: Lilja, H, i wsp.
Wydane: (2008)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
od: Savage, C, i wsp.
Wydane: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
od: Vickers, A, i wsp.
Wydane: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
od: Vickers, A, i wsp.
Wydane: (2010)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
od: Vickers, A, i wsp.
Wydane: (2011)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
od: Vickers, A, i wsp.
Wydane: (2009)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
od: Lilja, H, i wsp.
Wydane: (2011)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
od: Klein, R, i wsp.
Wydane: (2012)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
od: Botchorishvili, G, i wsp.
Wydane: (2009)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
od: Evans-Axelsson, S, i wsp.
Wydane: (2012)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
od: Ulmert, D, i wsp.
Wydane: (2008)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
od: Haese, A, i wsp.
Wydane: (2004)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
od: Bangma, C, i wsp.
Wydane: (2010)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
od: Challacombe, B, i wsp.
Wydane: (2009)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
od: Berglund Göran, i wsp.
Wydane: (2008-02-01)

Biology of prostate-specific antigen
od: Lilja, H
Wydane: (2003)

Biology of prostate-specific antigen.
od: Lilja, H
Wydane: (2003)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
od: Lilja, H, i wsp.
Wydane: (2007)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
od: Vickers, A, i wsp.
Wydane: (2010)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
od: Vickers, A, i wsp.
Wydane: (2010)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
od: Denmeade, SR, i wsp.
Wydane: (2003)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
od: Denmeade, SR, i wsp.
Wydane: (2003)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
od: Ulmert, D, i wsp.
Wydane: (2008)

Prostatic specific antigen for prostate cancer detection
od: Lucas Nogueira, i wsp.
Wydane: (2009-10-01)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
od: Robert J. Klein, i wsp.
Wydane: (2022-04-01)

Screening for prostate cancer.
od: Carlsson, S, i wsp.
Wydane: (2012)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
od: Michael Tzeng, i wsp.
Wydane: (2021-08-01)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
od: Vickers, A, i wsp.
Wydane: (2010)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
od: Aus, G, i wsp.
Wydane: (2004)

The Role of Prostate-Specific Antigen in Prostate Cancer Screening
od: Constantin Traian Vasile, i wsp.
Wydane: (2014-06-01)

Urological cancer: Time for another rethink on prostate cancer screening.
od: Vickers, A, i wsp.
Wydane: (2012)

Screening for prostate cancer: To the editor
od: Carlsson, S, i wsp.
Wydane: (2012)

Prostate cancer: estimating the benefits of PSA screening.
od: Vickers, A, i wsp.
Wydane: (2009)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
od: Steuber, T, i wsp.
Wydane: (2007)

Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men
od: Mahyar Ghafoori, i wsp.
Wydane: (2009-08-01)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
od: O'Brien, M, i wsp.
Wydane: (2011)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
od: Vickers, A, i wsp.
Wydane: (2009)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
od: Hugosson, J, i wsp.
Wydane: (2003)

[Isoforms of free prostate-specific antigen]
od: Haese, A, i wsp.
Wydane: (2004)

Isoforms of free prostate-specific antigen
od: Haese, A, i wsp.
Wydane: (2004)